Background: Psychiatric assessment of somatization (the tendency to experience and communicate psychological distress in the form of physical symptoms and to seek medical help for them) currently rests on DSM criteria. An alternative diagnostic and conceptual framework has been proposed by an international group of psychosomatic investigators. The aim of this study was to compare these new criteria (Diagnostic Criteria for Psychosomatic Research, DCPR) with DSM-IV in a population where a high prevalence of psychosocial problems is expected (functional gastrointestinal disorders, FGID). Method: One hundred and ninety consecutive patients with FGID in a tertiary care center were assessed according to DSM-IV and DCPR criteria. Results: The number of the 12 DCPR diagnoses was almost double that of DSM diagnoses. Only 9% of the patients were not identified by DCPR criteria, whereas this occurred in 25% of patients using DSM criteria. While patients who were given a DSM diagnosis frequently had additional DCPR diagnoses, many patients with DCPR syndromes did not fulfill any DSM criteria. Four DCPR syndromes appared to be particularly frequent and accounted for almost three quarters of the total diagnoses (alexithymia, persistent somatization, functional symptoms secondary to a psychiatric disorder, demoralization). Conclusions: The joint use of DSM and DCPR criteria was found to improve the identification of psychological factors in FGID. The results may pave the way for changes in DSM classification of somatoform disorders.

Keywords:
Functional gastrointestinal disorders, Irritable bowel syndrome, Functional dyspepsia, Somatization, Diagnostic Criteria for Psychosomatic Research, Somatoform disorders, Alexithymia, Anxiety disorders, Depressive disorders, Demoralization
1.
Lipowski ZJ: Somatization: The concept and its clinical application. Am J Psychiatry 1988;145:1358–1368.
2.
Kroenke K, Mangelsdorff D: Common symptoms in ambulatory care. Am J Med 1989;86:262–268.
3.
Kellner R: Psychosomatic syndromes, somatization and somatoform disorders. Psychother Psychosom 1994;61:4–24.
4.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 1994.
5.
Mayou R: Somatization. Psychother Psychosom 1993;59:69–83.
6.
Sensky T: Somatization: Syndromes or processes? Psychother Psychosom 1994;61:1–3.
7.
Fava GA: The concept of psychosomatic disorder. Psychother Psycosom 1992;58:1–12.
8.
Epstein RM, Quill TE, McWhinney IR: Somatization reconsidered. Arch Intern Med 1999;159:215–222.
9.
World Health Organization: The ICD-10 classification of mental and behavioural disorders. Geneva, World Health Organization, 1992.
10.
Escobar JI, Gara M, Cohen-Silver R, Waitzkin H, Holman A, Compton W: Somatisation disorder in primary care. Br J Psychiatry 1998;173:262–266.
11.
Kroenke K, Spitzer RL, DeFruy FV, Hahn SR, Linzer M, Williams JBW, Brody D, Davies M: Multisomatoform Disorder. An alternative to undifferentiated somatoform disorder for the somatizing patient in primary care. Arch Gen Psychiatry 1997;54:352–358.
12.
Fava GA, Freyberger H, Bech P, Chistodoulou G, Sensky T, Theorell T, Wise TN: Diagnostic criteria for use in psychosomatic research. Psychother Psychosom 1995;63:1–8.
13.
Drossman DA, Creed FH, Fava GA, Olden KW, Patrick DL, Toner BB, Whitehead WE: Psychosocial aspects of the functional gastrointestinal disorders. Gastroenterol Int 1995;8:47–90.
14.
North CS, Alpers DH, Thompson SJ, Spitznagel EL: Gastrointestinal symptoms and psychiatric disorders in the general population. Findings from NIMH Epidemiological Catchment Area Project. Dig Dis Sci 1996;41:633–640.
15.
Bennett EJ, Piesse C, Palmer K, Badcok CA, Tennant CC, Kellow JE: Functional gastrointestinal disorders; psychological, social, and somatic features. Gut 1998;42:414–420.
16.
Hochstrasser B, Angst J: The Zurich study: XXII. Epidemiology of gastrointestinal complaints and comorbidity with anxiety and depression. Eur Arch Psychiatry Clin Neurosci 1996;246:261–272.
17.
Bass C, Gill D, Sharpe M: Frequent attenders without organic disease in a gastroenterology clinic. Gen Hosp Psychiatry 1999;21:30–38.
18.
Fava GA, Porcelli P: Multisomatoform disorder (Letter of the Editor). Arch Gen Psychiatry 1998; 55:756.
19.
Drossman DA (ed): The Functional Gastrointestinal Disorders: Diagnosis, Pathophysiology, and Treatment. Boston, Little, Brown and Company, 1994.
20.
Spitzer RL, Williams JBW, Gibbon M, First MB: SCID Intervista strutturata per il DSM-III-R (Italian version by Fava M, Guaraldi GP, Mazzi F, Rigatelli M). Firenze, Organizzazioni Speciali, 1993.
21.
Freyberger HJ: Interview for Field Trials of Diagnostic Criteria for Psychosomatic Research (DCPR). Lubeck, University of Lubeck, 1995.
22.
Roy-Byrne P, Katon W, Broadhead WE, Lepine JP, Richards J, Brantley PJ, Russo J, Zinbarg R, Barlow D, Liebowitz M: Subsyndromal (mixed) anxiety-depression in primary care. J Intern Med 1994;9:507–512.
23.
Sifneos PE: The prevalence of alexithymic characteristics in psychosomatic patients. Psychother Psychosom 1973;22:255–262.
24.
Taylor GJ, Bagby RM, Parker JDA: Disorders of affect regulation. Alexithymia in medical and psychiatric illness. Cambridge, Cambridge University Press, 1997.
25.
Fava GA, Sonino N: Psychosomatic medicine: Emerging trends and perspectives. Psychother Psychosom 2000;69:184–197.
26.
Porcelli P, Taylor GJ, Bagby RM, De Carne M: Alexithymia and functional gastrointestinal disorder. Psychother Psychosom 1999;68:263–269.
27.
Bach M, Bach D: Alexithymia in somatoform disorders and somatic diseases. Psychother Psychosom 1996;65:150–152.
28.
Honkalampi K, Saarinen P, Hintikka J, Virtanen V, Viinamaki H: Factors associated with alexithymia in patients suffering from depression. Psychother Psychosom 1999;68:270–275.
29.
Iancu I, Horesh N, Offer D, Dannon PN, Lepkifker E, Kotler M: Alexithymia, affect intensity and emotional range in suicidal patients. Psychother Psychosom 1999;68:276–280.
30.
Berenbaum H, Davis R, McGrew J: Alexithymia and the interpretation of hostile-provoking situations. Psychother Psychosom 1998;67:254–258.
31.
Kooiman CG, Spinhoven P, Truiisburg RW, Roojmans HGM: Perceived parental attitude, alexithymia and defense style in psychiatric outpatients. Psychother Psychosom 1998;67:81–87.
32.
Fava GA, Magelli C, Savron G, Conti S, Bartolucci G, Grandi S, Semprini F, Saviotti FM, Belluardo P, Magnani B: Neurocirculatory asthenia. Acta Psychiatr Scand 1994;89:314–319.
33.
Engel GL: From biomedical to biopsychosocial. Psychother Psychosom 1997;66:57–62.
34.
Frank JD, Frank JB: Persuasion and Healing. Baltimore, Johns Hopkins University Press, 1991.
35.
de Figuereido JM: Depression and demoralization: Phenomenological differences and research perspectives. Comp Psychiatry 1993;34:308–311.
36.
Fava GA: Screening and diagnosis of depression. Dis Manage Health Outcomes 1997;2:1–7.
37.
Engel GL: Signs of giving-up; in Troup SB, Green WA (eds): The Patient, Death and the Family. New York, Scribners, 1994, pp 43–69.
38.
Engel GL: On looking inward and being scientific. A tribute to Arthur H. Schmale, MD. Psychother Psychosom 1990;54:63–69.
39.
Engel GL: Conversion symptoms; in Mac Bryde CM, Blacklow RS (eds): Signs and Symptoms. Philadelphia, Lippincott, 1970, pp 650–659.
40.
Drossman DA, Thompson WG: Irritable bowel syndrome: A graduated, multicomponent treatment approach. Ann Intern Med 1992;116:1009–1016.
41.
Smith RC, Greenbaum DS, Vancouver JB, Henry RC, Reinhart MA, Greenbaum RB, Dean HA, Mayle JE: Psychosocial factors are associated with health care seeking rather than diagnosis in irritable bowel sydrome. Gastroenterology 1990;98:293–301.
42.
Drossman DA, Whitehead WE, Camilleri M: Irritable bowel syndrome: A technical review for practice guideline development. Gastroenterology 1997;112:2120–2137.
43.
Lumley MA, Stettner L, Wehmer F: How are alexithymia and physical illness linked? A review and critique of pathways. J Psychosom Res 1996;41:505–518.
44.
Lumley MA, Tomakowsky J, Torosian T: The relationship of alexithymia to subjective and biomedical measures of disease. Psychosomatics 1997;38:497–502.
45.
Lumley MA, Norman S: Alexithymia and health care utilization. Psychosom Med 1996;58:197–202.
46.
Drossman DA, McKee DC, Sandler RS, Mitchell CM, Cramer EM, Lowman BC, Burger AL: Psychosocial factors in the irritable bowel syndrome: A multivariate study of patients and nonpatients with irritable bowel syndrome. Gastroenterology 1988;95:701–708.
47.
Whitehead WE, Bosmajian L, Zonderman AB, Costa PT, Schuster MM: Symptoms of psychologic distress associated with irritable bowel syndrome. Comparison of community and medical clinic samples. Gastroenterology 1988;95:709–714.
48.
Fava GA, Freyberger H (eds): Handbook of psychosomatic medicine. Madison, International University Press, 1998.
49.
Holtmann G, Goebell H, Talley NJ: Dyspepsia in consulters and non-consulters. Prevalence, health care seeking behavior and risk factors. Eur J Gastrointestinal Hepatol 1994;6:917–924.
50.
Drossman DA, Li Z, Andruzzi E, Temle RD, Talley NJ, Thompson WG, Whitehead WE, Janssens J, Funch-Jensen P, Corazziari E, Richter JE, Koch GG: US householder survey of functional gastrointestinal disorders. Dig Dis Sci 1993;38:1569–1580.
51.
Mayer EA, Fass R, Fullerton S: Intestinal and extraintestinal symptoms in functional gastrointestinal disorders. Eur J Surg 1998(suppl 583):29–31.
52.
Trimble KC, Farouk R, Pryde A, Douglas S, Heading RC: Heightened visceral sensation in functional gastrointestinal disease is non-site specific. Dig Dis Sci 1995;40:1607–1613.
53.
Fava GA: Subclinical symptoms in mood disorders. Psychol Med 1999;29:47–61.
54.
Fava GA, Mangelli L: Subclinical symptoms of panic disorder. Psychother Psychosom 1999;68:281–289.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.